{"transactions":[{"id":945504,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:30:21.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":1360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":2640,"derivative":{"underlying":"Common Stock","underlying_shares":1360},"source":{"system":"sec-edgar","filing":"0001193125-26-004573","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526004573/ownership.xml","form_type":"4"}},{"id":945503,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:30:21.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":700,"price":21.38,"value":14966.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":4682,"source":{"system":"sec-edgar","filing":"0001193125-26-004573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526004573/ownership.xml","form_type":"4"}},{"id":945502,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:30:21.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":1360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":5382,"source":{"system":"sec-edgar","filing":"0001193125-26-004573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526004573/ownership.xml","form_type":"4"}},{"id":1090449,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-08T20:00:08.000Z","date":"2025-07-03","kind":"exercise","planned":false,"acquired":false,"shares":1360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":1360},"source":{"system":"sec-edgar","filing":"0000950170-25-094576","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025094576/ownership.xml","form_type":"4"}},{"id":1090448,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-08T20:00:08.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":735,"price":3.38,"value":2484.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":4022,"source":{"system":"sec-edgar","filing":"0000950170-25-094576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025094576/ownership.xml","form_type":"4"}},{"id":1090447,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-08T20:00:08.000Z","date":"2025-07-03","kind":"exercise","planned":false,"acquired":true,"shares":1360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":4757,"source":{"system":"sec-edgar","filing":"0000950170-25-094576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025094576/ownership.xml","form_type":"4"}},{"id":1307424,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T21:00:03.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option will vest and become exercisable on January 3, 2026 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":16400,"derivative":{"exercise_price":5.7,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0000950170-25-002811","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025002811/ownership.xml","form_type":"4"}},{"id":1307423,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-07T21:00:03.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":2640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":5360,"derivative":{"underlying":"Common Stock","underlying_shares":2640},"source":{"system":"sec-edgar","filing":"0000950170-25-002811","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025002811/ownership.xml","form_type":"4"}},{"id":1307422,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-07T21:00:03.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":1341,"price":5.6,"value":7509.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":3397,"source":{"system":"sec-edgar","filing":"0000950170-25-002811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025002811/ownership.xml","form_type":"4"}},{"id":1307421,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-07T21:00:03.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":2640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":4738,"source":{"system":"sec-edgar","filing":"0000950170-25-002811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025002811/ownership.xml","form_type":"4"}},{"id":1387431,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-10-11T21:00:03.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":44100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in 48 equal monthly installments over four years from the Award Date, subject in each case to the grantee's continued service through the applicable vesting date."}],"balance_after":44100,"derivative":{"exercise_price":7.49,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":44100},"source":{"system":"sec-edgar","filing":"0000950170-24-114384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024114384/ownership.xml","form_type":"4"}},{"id":1685071,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-05T21:00:14.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc.  One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc.  One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":200000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-24-002433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024002433/ownership.xml","form_type":"4"}},{"id":2061559,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:00:41.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":300000,"derivative":{"exercise_price":1.21,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-23-001760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919123001760/doc4.xml","form_type":"4"}},{"id":2319648,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-23T12:00:12.000Z","date":"2022-03-22","kind":"purchase","acquired":true,"shares":5000,"price":2.15,"value":10750.0,"ownership":{"direct":true},"balance_after":52428,"source":{"system":"sec-edgar","filing":"0001209191-22-020682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919122020682/doc4.xml","form_type":"4"}},{"id":2440960,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T22:00:42.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":287500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":287500,"derivative":{"exercise_price":3.24,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":287500},"source":{"system":"sec-edgar","filing":"0001209191-22-002215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919122002215/doc4.xml","form_type":"4"}},{"id":2517115,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-10T13:00:10.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":4500,"price":3.5,"value":15750.0,"ownership":{"direct":true},"balance_after":47428,"source":{"system":"sec-edgar","filing":"0001209191-21-063798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919121063798/doc4.xml","form_type":"4"}},{"id":2655448,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-24T20:00:19.000Z","date":"2021-06-24","kind":"purchase","acquired":true,"shares":3000,"price":5.11,"value":15330.0,"ownership":{"direct":true},"balance_after":42928,"source":{"system":"sec-edgar","filing":"0001209191-21-042986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919121042986/doc4.xml","form_type":"4"}},{"id":2913222,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-07T21:00:14.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":230000,"derivative":{"exercise_price":13,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001209191-21-002476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919121002476/doc4.xml","form_type":"4"}},{"id":2992088,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series C-1 Preferred Stock","published_at":"2020-11-05T01:00:13.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":5359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13931},"source":{"system":"sec-edgar","filing":"0000899243-20-030412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030412/doc4.xml","form_type":"4"}},{"id":2992087,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-05T01:00:13.000Z","date":"2020-10-07","kind":"grant","acquired":true,"shares":519940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":519940,"derivative":{"exercise_price":7.7,"expiration_date":"2030-10-06","underlying":"Common Stock","underlying_shares":519940},"source":{"system":"sec-edgar","filing":"0000899243-20-030412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030412/doc4.xml","form_type":"4"}},{"id":2992086,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-05T01:00:13.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":207976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":207976,"derivative":{"exercise_price":1.95,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":207976},"source":{"system":"sec-edgar","filing":"0000899243-20-030412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030412/doc4.xml","form_type":"4"}},{"id":2992085,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":69926,"kind":"person","name":"Schambye Hans T.","position":1,"cik":"0001825776","reported_name":"Schambye Hans T.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-05T01:00:13.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":13931,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."}],"balance_after":39928,"source":{"system":"sec-edgar","filing":"0000899243-20-030412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030412/doc4.xml","form_type":"4"}}]}